Pfizer Inc. shares fell after it halted early development of an oral drug for weight loss on safety concerns, raising investor anxiety about an alternative therapy the company is still developing.
The drugmaker will stop work on lotiglipron based on data from phase 1 clinical trials and lab measurements showing elevated levels of enzymes called transaminases from an ongoing mid-stage stud…
Read more